• Imagin Medical’s contract manufacturer, Lighthouse Imaging, has developed a program focused on refining the i/Blue System’s design for manufacturing
• Lighthouse’s manufacturing process will ensure that regulatory standards are followed while maintaining optimal performance and staying within targeted costs
• Imagin is currently focusing on using the i/Blue system for bladder cancer visualization with plans to extend the use of the technology to other procedures in the future

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is on track to complete its patented i/Blue Imaging System(TM) in 2022. The innovative technology leverages proprietary light sensors and optics to improve the accuracy and efficiency of bladder cancer visualization and removal, potentially reducing recurrence rates.

The manufacturing progress reported to-date can be largely attributed to the company selecting Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified manufacturer, as its contract manufacturer. According to a press release, Lighthouse’s development program is focused on refining the i/Blue system’s design to ensure that the final device complies with all regulatory standards while maintaining optimal performance and remaining within a target cost and anticipated demand (https://ibn.fm/B6kXW). 

Imagin Medical Director of Engineering and Quality Mike Vergano explained that the company chose Lighthouse to help move the i/Blue System into commercial manufacturing because of its cross-functional expertise in electronics, optics, software and mechanical design. He added that Imagin was very satisfied with Lighthouse’s manufacturing progress: “We have not been disappointed. The Lighthouse team’s work to-date has been exceptional, and we look forward to that continuing.”

Imagin President and CEO Jim Hutchens also said his company expected Lighthouse to remain on schedule and meet all manufacturing targets. This year’s primary goal is the completion of the final pre-production i/Blue Imaging System unit, as outlined by Hutchens in a press release earlier this year. The company’s secondary goals include establishing final test parameters for the technology with the FDA, continuing to develop relationships with opinion leaders in the field and expanding its intellectual property platform (https://ibn.fm/ZwUKV). 

While the company has plans to expand its technology to other minimally invasive procedures, the primary focus for now is on bladder cancer, one of the most expensive forms of cancers to treat. Bladder cancer is the sixth most prevalent cancer in the U.S., with one of the highest recurrence rates, greater than 50%. In 2020, there were 81,400 new cases reported and approximately 17,980 deaths (https://ibn.fm/lwm6S). 

The current standard of treatment for bladder cancer is the cystoscopy, a procedure that allows doctors to examine the lining of the bladder by inserting a hollow tube (cystoscope) equipped with a lens into the bladder. Approximately 90% of all cystoscopies use white light which, however, cannot detect all of the cancerous growths if they run flush along the bladder’s lining. Introduced a decade ago, the use of an FDA-approved contrast agent with a blue light filter allows surgeons to better visualize flat surface cancerous growths, enabling a cleaner resection, but has the downside of not showing images in real time, requiring surgeons to switch back between white and blue light images to orient themselves within the bladder.

Imagin Medical’s innovative i/Blue Imaging System, based on advanced optics and light sensors that employ patented ultrasensitive imaging technology, aims to address these limitations by simultaneously displaying white light and blue light images in real time, side-by-side on the screen, providing better visualization for the surgeon and potentially lowering recurrence rates. Additionally, the i/Blue Imaging System adapts to most endoscopes already on the market, thus providing a more cost-effective solution for hospitals.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.